OneSkin is a San Francisco biotech and direct-to-consumer skincare company founded by four Brazilian women scientists who set out to slow skin aging at the molecular level. Its flagship OS-01 peptide - identified from a library of 900+ candidates using computational screening and tested on lab-grown human skin models - targets senescent 'zombie' cells that drive wrinkles, thinning and loss of firmness. The company sells topical 'supplements' for the face, eyes, body and sun protection, and frames skin not as a cosmetic surface but as the body's largest organ and a lever on overall healthspan.
MetaNovas (MetaNovas Biotech) is an AI-driven biotech company building a drug and disease discovery platform that compresses the slow, failure-prone front end of R&D. Its stack of proprietary engines - MetaNLP, MetaKG, MetaOmics and MetaPep - reads millions of scientific documents, maps biomedical knowledge, and designs bioactive peptides before anything reaches a lab bench. The company applies that science to longevity beauty, cosmeceuticals, medical aesthetics and functional foods, working with global brands while pursuing novel targets, drug repurposing and precision-formulated consumer health products.
Meijie Wang is the co-founder and CEO of MetaNovas, an AI-driven biotech that designs functional peptides for skincare, supplements and drug discovery. A former NVIDIA AI infrastructure engineer who built VR games and worked on AI at Stanford's School of Medicine, he now runs a Silicon Valley and Shanghai operation whose knowledge-graph platform aims to compress the decade-long hunt for new bioactive ingredients into something far shorter. MetaNovas counts L'Oreal, Beiersdorf, Haleon, Takeda and Unilever among its partners and raised a Series A led by GL Ventures.